Pyridines and derivatives
Apexbio Technology LLC Tigecycline 220620-09-7 25mg
Tigecycline is a glycylcycline-class antibiotic developed as a structural derivative of tetracycline antibiotics It exerts antimicrobial activity by reversibly binding to the bacterial 30S ribosomal subunit leading to inhibition of protein synthesis Tigecycline demonstrates bacterial growth inhibition in both Gram-positive and Gram-negative pathogens including multidrug-resistant strains In vitro studies showed minimal inhibitory concentration (MIC90) values ranging between 0 12-0 5 g/ml against vancomycin-sensitive and resistant Enterococcus faecalis and Enterococcus faecium In animal infection models using MRSA strains Tigecycline displays in vivo efficacy with an ED50 approximately 0 72 mg/kg This antibiotic is commonly employed in research studies focusing on resistant bacterial infections such as complicated skin infections and intra-abdominal infections
Apexbio Technology LLC Tigecycline 220620-09-7 100mg
Tigecycline is a glycylcycline-class antibiotic developed as a structural derivative of tetracycline antibiotics It exerts antimicrobial activity by reversibly binding to the bacterial 30S ribosomal subunit leading to inhibition of protein synthesis Tigecycline demonstrates bacterial growth inhibition in both Gram-positive and Gram-negative pathogens including multidrug-resistant strains In vitro studies showed minimal inhibitory concentration (MIC90) values ranging between 0 12-0 5 g/ml against vancomycin-sensitive and resistant Enterococcus faecalis and Enterococcus faecium In animal infection models using MRSA strains Tigecycline displays in vivo efficacy with an ED50 approximately 0 72 mg/kg This antibiotic is commonly employed in research studies focusing on resistant bacterial infections such as complicated skin infections and intra-abdominal infections
Apexbio Technology LLC MYCMI-6 681282-09-7 10mg
MYCMI-6 (CAS 681282-09-7) is a selective inhibitor of endogenous protein-protein interactions specifically targeting the basic helix loop helix leucine zipper (bHLHZip) domain of MYC with a binding affinity of 1 6 M By disrupting interactions at this domain MYCMI-6 blocks MYC-driven transcriptional activity The compound inhibits the proliferation of tumor cells in a MYC-dependent manner with IC50 values below 0 5 M while displaying no cytotoxicity toward normal human cells MYCMI-6 also induces apoptosis in treated cells It is utilized in research settings to investigate MYC function and the consequences of MYC inhibition in cancer biology
Apexbio Technology LLC MYCMI-6 681282-09-7 100mg
MYCMI-6 (CAS 681282-09-7) is a selective inhibitor of endogenous protein-protein interactions specifically targeting the basic helix loop helix leucine zipper (bHLHZip) domain of MYC with a binding affinity of 1 6 M By disrupting interactions at this domain MYCMI-6 blocks MYC-driven transcriptional activity The compound inhibits the proliferation of tumor cells in a MYC-dependent manner with IC50 values below 0 5 M while displaying no cytotoxicity toward normal human cells MYCMI-6 also induces apoptosis in treated cells It is utilized in research settings to investigate MYC function and the consequences of MYC inhibition in cancer biology
Apexbio Technology LLC MYCMI-6 681282-09-7 50mg
MYCMI-6 (CAS 681282-09-7) is a selective inhibitor of endogenous protein-protein interactions specifically targeting the basic helix loop helix leucine zipper (bHLHZip) domain of MYC with a binding affinity of 1 6 M By disrupting interactions at this domain MYCMI-6 blocks MYC-driven transcriptional activity The compound inhibits the proliferation of tumor cells in a MYC-dependent manner with IC50 values below 0 5 M while displaying no cytotoxicity toward normal human cells MYCMI-6 also induces apoptosis in treated cells It is utilized in research settings to investigate MYC function and the consequences of MYC inhibition in cancer biology
Apexbio Technology LLC MYCMI-6 681282-09-7 25mg
MYCMI-6 (CAS 681282-09-7) is a selective inhibitor of endogenous protein-protein interactions specifically targeting the basic helix loop helix leucine zipper (bHLHZip) domain of MYC with a binding affinity of 1 6 M By disrupting interactions at this domain MYCMI-6 blocks MYC-driven transcriptional activity The compound inhibits the proliferation of tumor cells in a MYC-dependent manner with IC50 values below 0 5 M while displaying no cytotoxicity toward normal human cells MYCMI-6 also induces apoptosis in treated cells It is utilized in research settings to investigate MYC function and the consequences of MYC inhibition in cancer biology
Medchemexpress LLC Tigecycline | 220620-09-7 | >98.0% | 50 MG
Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic used as a laboratory chemical for the manufacture of substances. It exhibits a mean inhibitory concentration (MIC) of approximately 125 ng/mL for E. coli (MG1655 strain) and MIC50 and MIC90 values of 1 and 2 mg/L, respectively, for Acinetobacter baumannii. This product is intended for research use only and has not been fully validated for medical applications.
- Broad-spectrum glycylcycline antibiotic
- Effective against E. coli (MG1655 strain) with an MIC of approximately 125 ng/mL
- Active against Acinetobacter baumannii with MIC50 and MIC90 values of 1 and 2 mg/L
- Classified as acutely toxic if swallowed (Category 4)
- Causes skin irritation (Category 2) and serious eye irritation (Category 2A)
- May cause respiratory irritation (Category 3)
- For research use only
Medchemexpress LLC Tigecycline | 220620-09-7 | 99.95% | 5 MG
Tigecycline is a broad-spectrum glycylcycline antibiotic, identified for use as a laboratory chemical and in the manufacture of substances. It exhibits inhibitory effects against various bacteria including *E. coli* and *Acinetobacter baumannii*, and has shown antileukemic activity in both in vitro and in vivo studies.
- Broad-spectrum glycylcycline antibiotic.
- Active against *E. coli* with a mean inhibitory concentration of 125 ng/mL.
- Effective against *Acinetobacter baumannii* with MIC50 and MIC90 of 1 and 2 mg/L respectively.
- Demonstrates inhibition of AML2 and HL-60 human leukemia cells.
- Reduces tumor volume and weight in an AML xenograft model.
Medchemexpress LLC Baricitinib | 1187594-09-7 | C16H17N7O2S | 25 MG
Baricitinib is a selective and orally bioavailable JAK1 and JAK2 inhibitor. This analytical standard is intended for research and analytical applications.
- Targets JAK2 (IC50: 5.7 nM) and JAK1 (IC50: 5.9 nM).
- Inhibits IL-6-stimulated phosphorylation of STAT3 (pSTAT3) and MCP-1 production in cell-based assays.
- Inhibits IL-23-stimulated pSTAT3 in isolated naive T-cells, preventing IL-17 and IL-22 production.
- In vivo, 1 mg/kg inhibits increases in hind paw volumes by 50%.
- Reduces inflammation, CD8 infiltration, and MHC class I and II expression in alopecia areata models.
Medchemexpress LLC Baricitinib | 1187594-09-7 | C16H17N7O2S | 500 MG
Baricitinib is a selective and orally bioavailable inhibitor of JAK1 and JAK2. This compound is intended for research applications, facilitating studies in inflammation and immunology.
- Selective and orally bioavailable JAK1 and JAK2 inhibitor
- IC50s of 5.9 nM for JAK1 and 5.7 nM for JAK2
- Molecular weight: 371.42
- Appearance: Solid
- Color: White to off-white
- Melting/freezing point: 212-215°C
- Relative density: 1.56 g/cm³
- Inhibits IL-6 induced MCP-1 production in peripheral blood mononuclear cells (IC50 40 nM)
- Inhibits pSTAT3 stimulated by IL-23 in isolated naive T-cells (IC50 20 nM)
- Prevents production of IL-17 and IL-22 by Th17 cells (IC50 50 nM)
Apexbio Technology LLC MYCMI-6 681282-09-7 5mg
MYCMI-6 (CAS 681282-09-7) is a selective inhibitor of endogenous protein-protein interactions specifically targeting the basic helix loop helix leucine zipper (bHLHZip) domain of MYC with a binding affinity of 1 6 M By disrupting interactions at this domain MYCMI-6 blocks MYC-driven transcriptional activity The compound inhibits the proliferation of tumor cells in a MYC-dependent manner with IC50 values below 0 5 M while displaying no cytotoxicity toward normal human cells MYCMI-6 also induces apoptosis in treated cells It is utilized in research settings to investigate MYC function and the consequences of MYC inhibition in cancer biology
Medchemexpress LLC Baricitinib | 1187594-09-7 | C16H17N7O2S | 50 MG
Baricitinib is a selective and orally bioavailable inhibitor of JAK1 and JAK2, widely used in research for its role in epigenetic and JAK/STAT signaling pathways.
- Selective JAK1 and JAK2 inhibitor
- Molecular weight of 371.42
- Inhibits IL-6-stimulated STAT3 phosphorylation
- Prevents IL-23 stimulated production of IL-17 and IL-22 by Th17 cells
- Active in vivo, reducing inflammation and hind paw volumes in animal models
- Stable as a powder for 3 years at -20°C, 2 years at 4°C
- Stable in solvent for 1 year at -80°C, 6 months at -20°C
- Soluble in DMSO (in vitro) and various solutions for in vivo applications
- Solid appearance
- Melting point 212-215°C
- Relative density 1.56 g/cm³
Medchemexpress LLC Tigecycline | 220620-09-7 | 99.95% | 1 ML
Tigecycline is a broad-spectrum glycylcycline antibiotic. It demonstrates inhibitory activity against various bacterial strains such as *E. coli* and *Acinetobacter baumannii*, and also inhibits AML2 and HL-60 cells in vitro. In vivo studies have shown that Tigecycline can reduce tumor volume and weight in acute myeloid leukemia xenograft models.
- Broad-spectrum glycylcycline antibiotic
- Inhibits *E. coli* and *A. baumannii*
- Demonstrates in vitro activity against AML2 and HL-60 cells
- Reduces tumor volume and weight in AML xenograft models
Medchemexpress LLC Tigecycline | 220620-09-7 | 99.9% | 500 MG
Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. It demonstrates activity against various bacteria, including E. coli with a mean inhibitory concentration (MIC) of approximately 125 ng/mL, and Acinetobacter baumannii with MIC50 and MIC90 values of 1 and 2 mg/L, respectively. In vitro studies show Tigecycline inhibits AML2 and HL-60 human leukemia cells. In vivo, it has been shown to reduce tumor volume and weight in NOD/SCID mice models of acute myeloid leukemia. Pharmacokinetic studies in mice indicate a Cmax of 22.8 μg/mL and a terminal half-life of 108.9 min in saline.
- Broad-spectrum glycylcycline antibiotic
- Inhibits AML2 and HL-60 human leukemia cells in vitro
- Reduces tumor volume and weight in NOD/SCID mice xenograft models
- Well-characterized pharmacokinetic profile in animal models
Apexbio Technology LLC Baricitinib (LY3009104, INCB028050) 1187594-09-7 50mg
Baricitinib (LY3009104 INCB028050 CAS 1187594-09-7) is an orally bioavailable ATP-competitive inhibitor targeting Janus kinases JAK1 and JAK2 It also exhibits moderate inhibition of TYK2 and weaker inhibition against JAK3 In biochemical assays baricitinib inhibits JAK1 and JAK2 with IC50 values of 5 9 nM and 5 7 nM respectively At concentrations below 50 nM baricitinib suppresses intracellular signaling mediated by several pro-inflammatory cytokines notably IL-6 and IL-23 Due to its mechanistic profile baricitinib is actively explored in inflammatory disease research such as rheumatoid arthritis